Crinetics Pharmaceuticals, Inc.
CRNX
Rang in aandelen
#2195
Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical... Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical enterprise, dedicated to the identification, advancement, and market introduction of therapeutic solutions for infrequent endocrine conditions and related tumors. Their flagship drug candidate, Paltusotine, is an orally administered, selective, non-peptide somatostatin receptor type 2 agonist. This compound has concluded its Phase III clinical trials for the treatment of acromegaly, and has also completed Phase II trials targeting carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). Furthermore, the company's pipeline includes CRN04777, an oral selective non-peptide somatostatin type 5 receptor agonist, which is currently undergoing Phase I clinical trials for congenital hyperinsulinism. Another investigational drug, CRN04894, an oral adrenocorticotrophic hormone antagonist, is in Phase I clinical trials for Cushing's disease and congenital adrenal hyperplasia. Crinetics Pharmaceuticals, Inc. was founded in 2008 and maintains its headquarters in San Diego, California.
Aandeelprijs
$84.95
Laatst gesynchroniseerd: 2026-09-01
Marktkapitalisatie
$9.00B
Verandering (1 dag)
0.00%
Verandering (1 jaar)
110.12%
Land
US
Handel Crinetics Pharmaceuticals, Inc. (CRNX)
Categorie
Healthcare
Koersgeschiedenis voor Crinetics Pharmaceuticals, Inc. (CRNX)
Hoogste slotkoers: $84.95 op 2026-09-01
Laagste slotkoers: $24.52 op 2018-07-01
Laagste slotkoers: $24.52 op 2018-07-01
Koersgeschiedenis van Crinetics Pharmaceuticals, Inc. van 2018 tot 2026
Jaarlijkse koersprestatie
| Jaar | Prestaties |
|---|---|
| 2026 (TTM) | 3.89% |
| 2025 | -13.25% |
| 2024 | 59.38% |
| 2023 | 103.03% |
| 2022 | -34.46% |
| 2021 | 91.75% |
| 2020 | -37.94% |
| 2019 | -30.68% |
| 2018 | 0.00% |
Aandelenkoers van vergelijkbare bedrijven of concurrenten
| Bedrijf | Aandelenkoers | Verandering 1jr% | Land |
|---|---|---|---|
| $535.37 | 25.54% |
US
|
|
| $185.00 | 589.01% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $291.76 | 2.51% |
BE
|
|
| $885.21 | 8.73% |
NL
|
